38 articles tagged with "health"
A recent study suggests that postponing primary school enrollment may enhance educational and health results for children in low-income nations.
The Centers for Medicare & Medicaid Services (CMS) is considering the repeal of a payment pathway that currently provides supplementary payments for breakthrough devices.
This overview delves into employer-sponsored health insurance (ESI), which serves as the main health coverage for U.S. residents under 65, detailing its structure and costs.
The U.S. Global Health Country-Level Funding Tracker offers detailed insights into funding allocations across various health programs and countries.
In recent biotech news, the CEO of Novartis has joined the board of Anthropic, alongside updates on Revolution Medicines' significant fundraising and Structure's potential acquisition moves.
An external advisory panel will convene to assess the implications of permitting compounding pharmacies to produce specific peptides.
This edition of STAT's AI Prognosis discusses a $15 AI test, the implications of Project Glasswing for healthcare, and insights into Doctronic's AI pilot in Utah.
Eli Lilly's obesity treatment, Foundayo, is under increased scrutiny as the FDA seeks more data regarding potential liver injury risks associated with the drug.
A recent report from the Trump administration's Department of Justice claims that the Biden administration has treated anti-abortion protestors unfairly. This report raises questions about the handling of such demonstrations.
Beeline Medicine, a new biotech startup, is set to develop a series of drugs targeting inflammatory and immune disorders, beginning with a daily pill for lupus.
AI technology has the potential to analyze numerous CT scans for heart disease risk. However, questions remain regarding funding and the effectiveness of these tools in improving patient outcomes.
A recent analysis of a study on the antidepressant Paxil raises important questions about how concerns are communicated in scientific journals. Ed Silverman emphasizes the need for prominence in such disclosures.
The disconnect between MAHA and public health is concerning. A new podcast aims to facilitate necessary conversations between these critical sectors.
“Patients don’t experience illness in a vacuum,” writes Uché Blackstock.
As Congress resumes its sessions, several significant health care issues are on the agenda that warrant close attention.
A recent global study delves into the complex ethical question of whether to prioritize saving more lives or extending the years of life for fewer individuals, potentially impacting public health policies.
A high school student's innovative teabag design seeks to address the pressing issue of arsenic contamination in drinking water, potentially aiding millions worldwide.
In a recent development, the FDA is intensifying its efforts to ensure that drug manufacturers report the results of their clinical trials. This move comes amidst discussions on various biotech advancements.
Amid the growing influence of AI technologies like ChatGPT, hospitals are launching their own chatbots to improve patient interaction and accessibility.
In a significant move towards enhancing transparency in clinical research, the FDA has mandated that over 2,200 companies and researchers report their clinical trial results, with warnings of potential fines for non-compliance.
This editorial examines the insights gained from Medicaid unwinding that may assist states in implementing work requirements effectively.
Recent reports indicate a shortage of fluoride affecting certain water systems across the U.S., raising health concerns. This issue is part of broader health news covered in Morning Rounds.
The director of the WHO's Eastern Mediterranean region is contemplating a bid for the director-general position as tensions rise over the situation in Iran and surrounding areas.
As Dana-Farber Cancer Institute charts its course away from Mass General Brigham, CEO Benjamin Ebert shares his vision for a new hospital and the future of cancer care.
The recent approval of a breakthrough drug for a rare disease highlights ongoing issues in access, particularly for adult patients.
Revolution Medicines announced that its pancreatic cancer drug has shown success in a crucial Phase 3 trial, raising hopes for patients and the medical community.
In a significant move, Maryland's State Affordability Board has initiated a process to establish a price cap for Jardiance, a medication for type 2 diabetes, with a target date set for January 2027.
An FDA analysis reveals that almost 30% of clinical trials, likely subject to mandatory reporting, have not submitted their results, prompting calls for accountability from drug manufacturers.
A federal judge has dismissed a lawsuit related to the California No Surprises Act against HaloMD, a key player in out-of-network billing disputes for medical providers.
A remote patient monitoring company is adapting its technology to participate in Medicare's ACCESS experiment, which aims to improve health care outcomes through aligned payments.
Despite President Trump's promises to challenge health insurers, his policies appear to contradict those commitments, suggesting a softer stance.
In a recent trial, patients with metastatic pancreatic cancer who received a new medication from Revolution Medicines reportedly lived twice as long as those treated with chemotherapy.
As the healthcare landscape evolves, the transition of nurses into expert roles presents both opportunities and challenges, with implications for future healthcare delivery.
Recent findings indicate that Allogene Therapeutics’ CAR-T therapy effectively targets residual cancer cells in B-cell lymphoma patients, potentially delaying recurrence.
Spyre Therapeutics has reported positive results from its first major trial of a drug aimed at treating inflammatory bowel disease, positioning itself against larger pharmaceutical companies.
Several hospitals are beginning to implement chatbots, a bold move intended to enhance communication with existing patients while attracting new ones.
Erectile dysfunction extends beyond mere sexual concerns, impacting various aspects of life and well-being.
The position of head of the FDA's Center for Biologics Evaluation and Research presents significant challenges for any successor.